Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study

Table 3 Indication for biologic, concomitant therapies and premedication

Patients treated with IFX (total 125)
Indication for IFX
Steroid-dependent	77 (61.6%)
Steroid-resistant	16 (12.8%)
Rescue therapy severe UC	3 (2.4%)
EIM	0
Failure of thiopurine	12 (9.6%)
Fistulizing disease	7 (5.6%)
Prevention of postoperative recurrence	1 (0.8%)
Indication for IFX (dual indication)
Steroid-dependent + EIM	3 (2.4%)
Steroid-dependent + failure of thiopurine	3 (2.4%)
Steroid-dependent + fistulzing disease	1 (0.8%)
Fistulizing disease + EIM	2 (1.6%)
Total infusions (mean)	20 (range: 4-60)
Short infusion (mean)	6.1 (range: 1-19)
Concomitant therapies
None	12 (9.6%)
Steroids	25 (20%)
Thiopurine	10 (8%)
Methotrexate	2 (1.6%)
5ASA	56 (44.8%)
Concomitant therapies (polipharmacy)
Steroids + thiopurine	1 (0.8%)
Steroids + 5ASA	4 (3.2%)
Steroids + thiopurine + 5ASA	3 (2.4%)
Thiopurine/methotrexate + 5ASA	12 (9.6%)
Total use of steroids	33 (26.4%)
Total COMBO therapy (Thiopurine or Mtx)	28 (22.4%)
Total use of mesalamine	75 (60%)
Premedication
None	57 (45.6%)
Steroids	51 (40.8%)
Antihistaminic	1 (0.8%)
Steroids + antihistaminic	16 (12.8%)
Time of premedication
None	57 (45.6%)
From first infusion	65 (52%)
From second Infusion	3 (2.4%)
Only short infusion	0

IFX: Infliximab; EIM: Excitability-inducing material; UC: Ulcerative colitis; 5ASA: 5-aminosalicylates.